Advertisement

Topics

Roche's Herceptin facing further biosimilar threats in US

07:53 EDT 2 Aug 2017 | pharmaphorum

Roche’s breast cancer blockbuster Herceptin could face further competition in the US when its patent expires in the coming years, as Amgen-Allergan and Teva-Celltrion said the FDA accepted filings for cheaper biosimilar near-copies. With sales o...

Original Article: Roche's Herceptin facing further biosimilar threats in US

NEXT ARTICLE

More From BioPortfolio on "Roche's Herceptin facing further biosimilar threats in US"

Quick Search
Advertisement
 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...